<a href="https://www.fiercebiotech.com/biotech/after-rare-disease-flop-cash-strapped-quince-finds-salvation-reverse-merger" hreflang="en">After rare disease flop, cash-strapped Quince finds salvation in reverse merger </a>
fiercebiotech.com·May 18, 2026
Quince Therapeutics has decided to merge with private pulmonary startup Orphai Therapeutics as its exit strategy after exploring strategic alternatives following a failed phase 3 trial for a rare disease.
For someone tracking healthtech and biotech, the merger of Quince Therapeutics with Orphai Therapeutics suggests a strategic pivot often necessary after clinical setbacks, highlighting the importance of adaptive strategies in biotech investments. Keep an eye on how this merger affects their pipeline and market position, as it may signal new opportunities in pulmonary therapeutics.